Systematic literature review and meta-analysis of lotilaner 0.25% and tea tree oil for

Document Type

Article

Publication Date

10-14-2026

Publication Title

Front Ophthalmol (Lausanne)

Abstract

INTRODUCTION:

METHODS: MEDLINE, EMBASE, Cochrane CENTRAL, ClinicalTrials.gov, and ICTRP were searched from inception through July 10, 2025, to identify randomized controlled trials of lotilaner 0.25% or TTO.

RESULTS: Nine randomized controlled trials were included, with four evaluating lotilaner 0.25% versus vehicle and five evaluating TTO versus sham, comprising a total of 1,513 patients. Compared with vehicle, lotilaner 0.25% produced significantly lower mite density (mean difference -1.29 mites/lash at both 2-4 and 6-8 weeks; p< 0.0001) and significantly higher odds of mite eradication (OR 4.70 at 2-4 weeks; OR 9.60 at 6-8 weeks), collarette reduction to 0-2 collarettes (OR 8.39 and 9.67), and erythema cure at 6-8 weeks (OR 3.91; all p< 0.0001). TTO did not demonstrate a statistically significant difference versus sham for mite density or mite eradication at either timepoint.

DISCUSSION: These findings demonstrate a consistent, statistically significant benefit of lotilaner 0.25% across assessed outcomes compared with vehicle, supporting lotilaner 0.25% as an effective pharmacological treatment for DB. In contrast, randomized TTO studies were heterogeneous in product concentration, dosing regimen, and sham comparators and did not demonstrate a statistically significant effect on mite density or mite eradication versus sham comparators.

Volume

6

First Page

1978403

DOI

10.3389/fopht.2026.1978403

ISSN

2674-0826

PubMed ID

42952720

Share

COinS